Dr William Burch

William is Medical Manager at Clinuvel, a global biopharmaceutical company specialising in pigmentation disorders. Currently working in a Clinical Development, he also has experience in Medical Affairs. Before joining the pharmaceutical industry he completed Foundation training in the UK and undertook several positions in Medical Oncology and Early Phase Clinical Research. He holds a medical degree from University College London.

Dr Patrick De Barr

Patrick is a Senior Medical Director at Incyte Biosciences, a biopharmaceutical company and has held several roles in industry across Medical Affairs, Clinical Research and Clinical Operations. He holds a Medical Degree from the University of Nottingham and an MBA from Imperial College. Prior to joining the pharmaceutical industry, Patrick worked as an Intensive Care physician in the NHS. Since completing PMST in 2023, Patrick has an additional role at the National Institute of Health and Care Excellence (NICE) as a Pharmaceutical Physician, appraising new technology for use in the NHS.

Dr Andrew Harper

Andrew Harper uses deep scientific expertise and global clinical experience to drive the development of innovative medicines. As Senior Medical Director at AstraZeneca, he has successfully led teams in identifying genomically-anchored drug targets and advancing the clinical R&D pipeline.

Andrew holds an MSc in Medical Genetics and an MBBS from Newcastle University, and a DPhil from the University of Oxford, where his research redefined the genetic basis of hypertrophic cardiomyopathy. He is currently pursuing an MBA at Imperial College Business School.

His career at AstraZeneca includes pivotal roles in early clinical development and at the Centre for Genomics Research. Andrew has published over 50 manuscripts, advancing the understanding of genetic factors that underpin health and disease.

He is a member of the Faculty of Pharmaceutical Medicine and the Royal College of Physicians.

Dr Luke Kuttschreuter

Dr Luke Kuttschreuter is a pharmaceutical physician with a passion for innovation and patient-centricity. Luke received his medical degree in South Africa with preclinical and clinical distinctions from the University of Cape Town. After an early career mainly in anaesthesia, he moved to the UK where he earned his MSc in Pharmacology, focussed on preclinical target validation in DNA damage repair mechanisms, at the University of Oxford Department of Oncology. At the same time, Luke worked as a sub-investigator in the Oncology Early Phase Trials Unit.

Luke has since worked exclusively for Pfizer Oncology, gaining experience in Medical Affairs and Clinical Development roles. In these roles Luke gained extensive experience in the development of biologics and small molecule medicines in haematologic and solid tumour oncology. Two particular areas Luke enjoyed leading were paediatric development for a compound and an Early Access to Medicines Scheme.

Luke’s most passionate work has focussed on patient and caregiver involvement in the design and conduct of clinical research, especially early phase trials and novel pre-approval non-interventional studies, for which he has won multiple company awards. Luke has also led workstreams within the company and collaborated with the ABPI, NHS-England, HRA, and the NCRI on innovative research methods in Early Access settings, optimising the patient experience while ensuring ethical and equitable access.

Being in the first cohort to complete PMST under the new 2021 curriculum, and earning his DPM in 2021, Luke completed PMST early through the accelerated CCT route and entered the GMC Specialist Register earlier this year. Luke has also been awarded his Fellowship (FFPM) this year.

In July, Luke will be starting a new role as the Clinical Lead for an AI-powered oncology early development programme at the TechBio, Owkin.

Dr David Steel

David qualified as a physician from The University of Edinburgh and worked for NHS Scotland before moving to London to pursue a Master’s degree in Politics, Philosophy and Economics of Health at UCL and begin his career in Pharmaceutical Medicine.

Having obtained the Diploma in Pharmaceutical Medicine in 2020 before enrolling on PMST, he went on to become the first trainee to complete training on an accelerated 3-year program and one of the first trainees to complete PMST entirely on the new 2021 curriculum.

Currently serving as the Medical Director of the Parexel Early Phase Unit in London, he leads a team of 9 research physicians. He has been authorised to act as a Principal Investigator on First in Human trials since 2021 and has contributed to the delivery of over 70 early phase trials.

Leveraging his extensive early phase clinical development experience and expertise in Politics, Philosophy and Economics of Heath, David has also served as a member of the London Bridge Ethics Committee since 2020. He has a particular interest in medical ethics and patient involvement in early phase development.

David is also a Member of the Royal College of Physicians (MRCP), holds a Diploma in Tropical Medicine from the London School of Tropical Medicine and Hygiene, and is close to completing an MBA.

He is currently working towards becoming an Educational Supervisor for PMST with the aim of nurturing and inspiring other pharmaceutical physicians to pursue their own further professional development in the specialty.

David is eternally grateful to all the Pharmaceutical Physicians who have inspired and encouraged him on this journey, with special thanks to his educational supervisor Naz Tadayon, and his mentor and colleague Peter Dewland